Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Yopp JM, Park EM, Edwards T, Deal A, Rosenstein DL. Overlooked and underserved: widowed fathers with dependent-age children. Palliat Support Care. 2015 Oct;13(5):1325-34. doi: 10.1017/S1478951514001321